Vnitr Lek 2022, 68(2):131-134 | DOI: 10.36290/vnl.2022.025

Pharmacological possibilities of vitamin C in oncology

Marek Lapka
Ústav farmakologie 3. lékařské fakulty UK, Praha

Ascorbic acid is a well-described molecule which acts as a cofactor in many reactions and mediates a variety of biological functions. Despite its simple structure, vitamin C has a wide range of interesting effects that bring enormous potential to the clinical practice. The article summarizes available data on efficacy and safety in oncology.

Keywords: vitamin C, pharmacology, effect, safety, oncology.

Published: April 4, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lapka M. Pharmacological possibilities of vitamin C in oncology. Vnitr Lek. 2022;68(2):131-134. doi: 10.36290/vnl.2022.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res.1996;145,532-541. Go to original source...
    2. Li Y, Schellhorn HE. New developments and novel therapeutic perspectives for vitamin C. J Nutr. 2007;137:2171-84. Go to original source... Go to PubMed...
    3. Jacob RA, Sotoudeh G. Vitamin C function and status in chronic disease. Nutr Clin Care. 2002;5:66-74. Go to original source... Go to PubMed...
    4. Gershoff SN. Vitamin C (ascorbic acid): new roles, new requirements? Nutr Rev. 1993; 51:313-26. Go to original source... Go to PubMed...
    5. Stephen R, Utecht T. Scurvy identified in the emergency department: a case report. J Emerg Med. 2001;21:235-7. Go to original source... Go to PubMed...
    6. Wang AH, Still C. Old world meets modern: a case report of scurvy. Nutr Clin Pract. 2007;22:445-8. Go to original source... Go to PubMed...
    7. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005; 19: 17-20 Go to original source... Go to PubMed...
    8. Oak AS, Jaleel T, Fening K et al. 2016. A case of scurvy associated with nilotinib. J. Cut Pathol. 43;725-726. Go to original source... Go to PubMed...
    9. Shenoy N, Bhagat T, Nieves E, et al. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J.2017;7:e587. Go to original source... Go to PubMed...
    10. Pullar JM, Carr AC, Bozonet SM, et al. High Vitamin C Status Is Associated with Elevated Mood in Male Tertiary Students. Antioxidants (Basel). 2018;7(7):91. Go to original source... Go to PubMed...
    11. Du JJ, Cullen GR et al. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta. 2012;1826:443-457. Go to original source... Go to PubMed...
    12. Buettner GR and Schafer FQ. Ascorbate as an Antioxidant in Vitamin C. In: Asard H, May JM and Smirnoff N, Eds., Functions and Biochemistry in Animals and Plants, Bios Scientific Publishers. 2004.173-188. Go to original source...
    13. Chen Q, Espey MG, Sun AY et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proceedings of the National Academy of Sciences of the USA. 2008;105:11105-11109. Go to original source... Go to PubMed...
    14. Klimant E, Wright H, Rubin D. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr Oncol. 2018;25:39-148. 3. Go to original source... Go to PubMed...
    15. Böttger F, Vallés‑Martí A, Cahn L et al. High‑dose intravenous vitamin C, a promising multi‑targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021;40(1):343. Go to original source... Go to PubMed...
    16. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients' health‑related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007;22:7-11. Go to original source... Go to PubMed...
    17. Vollbracht C, Schneider B, Leendert V, et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25:983-90. Go to PubMed...
    18. Takahashi H, Mizuno H, Yanagisawa A. High‑dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe. 2012;1:49-53. Go to original source...
    19. Ngo B, Van Riper JM, Cantley CL et al. Targeting cancer vulnerabilities with high‑dose vitamin C. Nature Reviews Cancer. 2019;19:271-282. Go to original source... Go to PubMed...
    20. Wang F, He MM, Wang ZX et al. Phase I study of high‑dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer. 2019;19:460. Go to original source... Go to PubMed...
    21. Welch JS, Klco JM, Gao F et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. AJH. 2011;86:796-800. Go to original source... Go to PubMed...
    22. Aldoo I, Mark L, Vrona J et al. Adding ascorbic acid or arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol. 2014;93:1839-1843. Go to original source... Go to PubMed...
    23. Zhao H, Zhu H, Huang J et al. The synergy of vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1-7. Go to original source... Go to PubMed...
    24. Das AB, Kakadia PM, Wojcik D et al. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. Blood Cancer. 2019;9:82. Go to original source... Go to PubMed...
    25. Gill HS, Yim R, Kumana CR et al. Oral arsenic trioxide, all‑trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: long‑term results and unique prognostic indicators. Cancer. 2020;126:3244-3254. Go to original source... Go to PubMed...
    26. Khaw KT, Bingham S, Welch A et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC‑Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet. 2001;357:657-663. Go to original source... Go to PubMed...
    27. Ma Y, Chapman J, Levine M et al. High‑dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6:222ra18. Go to original source... Go to PubMed...
    28. Padayatty SJ, Sun AY, Chen Q et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5:e11414. Go to original source... Go to PubMed...
    29. Hoffer LJ, Levine M, Assouline S, et al. Phase i clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969-1974. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.